Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C64H83N17O13 |
Molecular Weight | 1298.4499 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](CC4=CC=C(O)C=C4)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(N)=O
InChI
InChIKey=BDPDXFSIFWZPCE-PHOVXGMNSA-N
InChI=1S/C64H83N17O13/c1-34(2)26-48(57(88)73-46(20-13-25-69-63(67)68-5)56(87)74-47(55(66)86)29-39-32-70-44-18-11-9-16-42(39)44)78-64(94)81-80-61(92)50(27-37-14-7-6-8-15-37)77-62(93)54(35(3)82)79-60(91)52(31-53(65)85)76-59(90)51(30-40-33-71-45-19-12-10-17-43(40)45)75-58(89)49(72-36(4)83)28-38-21-23-41(84)24-22-38/h6-12,14-19,21-24,32-35,46-52,54,70-71,82,84H,13,20,25-31H2,1-5H3,(H2,65,85)(H2,66,86)(H,72,83)(H,73,88)(H,74,87)(H,75,89)(H,76,90)(H,77,93)(H,79,91)(H,80,92)(H3,67,68,69)(H2,78,81,94)/t35-,46+,47+,48+,49-,50+,51-,52+,54+/m1/s1
Molecular Formula | C64H83N17O13 |
Molecular Weight | 1298.4499 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 5 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue. | 1999 Sep 10 |
|
A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization. | 2000 Dec 29 |
|
Leukotrienes modulate cytokine release from dendritic cells. | 2005 Dec |
|
4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK. | 2010 Jan 15 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:42:35 GMT 2023
by
admin
on
Sat Dec 16 11:42:35 GMT 2023
|
Record UNII |
K56X3P8P9Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TAK-683
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | MedKoo CAT NO: 202723, CAS NO: 872719-49-8Description: TAK-683 is an investigational peptide derivative of metastin that has been shown preclinically to be a potent metastin/GPR54 agonist both in vitro and in vivo. Administration of TAK-683 to male rats for 4 or 8 weeks has been shown to deplete GnRH in the hypothalamus and to reduce plasma FSH, LH and testosterone concentrations. The metastin analogue TAK-683 may be a promising candidate for further investigation in clinical trials in prostate cancer. A related metastin analogue, TAK-448, is also being evaluated in animal studies and in phase 1 clinical trials in prostate cancer (last updated: 7/13/2015). | ||
|
49787129
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | |||
|
K56X3P8P9Q
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY | |||
|
872719-49-8
Created by
admin on Sat Dec 16 11:42:35 GMT 2023 , Edited by admin on Sat Dec 16 11:42:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Functional assay
EC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
BINDING
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Drug: TAK 683(Primary); Indication: Prostate cancer; Focus: Adverse reactions; Most Recent Events: 23 Aug 2012 New trial record, 18 Jul 2012 Results published in the British Journal of Clinical Pharmacology.
|
||
|
ACTIVE MOIETY |
Originator: Takeda; Developer: Millennium; Class: Antineoplastic; Mechanism of Action: KISS1R protein agonist; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: Discontinued for Prostate cancer; Most Recent Events: 07 Apr 2009 Phase I development is ongoing in the UK
|
||
|
ACTIVE MOIETY |
TAK-683 was well tolerated up to a dose of 2.0 mg day1 by continuous s.c. infusion for 14 days. Adverse events were similar between TAK-683 and placebo subjects at all dose levels. TAK-683 plasma concentrations generally increased in proportion to dose with single and continuous dosing, with steady-state concentrations achieved by day 2 of continuous dosing. TAK-683 at 2.0 mg day1 suppressed testosterone below castration level (<50 ng dl1) in four of five subjects by day 7 of continuous dosing. Luteinizing hormone and follicle stimulating hormone concentrations were suppressed with TAK-683 continuous dosing compared with placebo by up to 70 and 43%, respectively, but this was not consistently dose-dependent.
|